Increase in serum mitochondrial creatine kinase levels induced by tenofovir administration
Recently, 2 monoclonal antibodies that specifically inhibit mitochondrial creatine kinase (MtCK) activity have been developed. In this study, we measured the serum MtCK activity in HIV-1-infected individuals (n = 100) by employing a novel method using these antibodies. The mean serum MtCK activity in 44 patients treated with highly active antiretroviral therapy (HAART) including tenofovir disoproxil fumarate (TDF) was 16.0 IU/L. The MtCK activity was significantly higher in patients receiving TDF than in those receiving HAART without TDF (3.4 IU/L) or in naïve patients (6.9 IU/L) (Tukey-Kramer test, p < 0.0001 and p = 0.0029, respectively). The serum MtCK activity reached a plateau at 1 month after the initiation of TDF administration and decreased upon discontinuation. It showed no significant correlation with the trough plasma TDF concentration, serum creatinine level, or red blood cell count. The activity was elevated in 75% of the patients receiving TDF, and this elevation was specific to TDF; it was not observed with other anti-HIV drugs. In addition, our report emphasizes the careful interpretation of creatine kinase-MB (CK-MB) test results in patients receiving TDF because MtCK in serum could cause false-positive results on a conventional CK-MB test, which does not include MtCK-specific inhibitory antibodies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2012 |
|---|---|
| Erschienen: |
2012 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy - 18(2012), 5 vom: 21. Okt., Seite 675-82 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Watanabe, Dai [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
99YXE507IL |
|---|
| Anmerkungen: |
Date Completed 01.07.2013 Date Revised 09.05.2018 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10156-012-0393-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM215575326 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM215575326 | ||
| 003 | DE-627 | ||
| 005 | 20231224025804.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10156-012-0393-8 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0718.xml |
| 035 | |a (DE-627)NLM215575326 | ||
| 035 | |a (NLM)22350406 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Watanabe, Dai |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Increase in serum mitochondrial creatine kinase levels induced by tenofovir administration |
| 264 | 1 | |c 2012 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.07.2013 | ||
| 500 | |a Date Revised 09.05.2018 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Recently, 2 monoclonal antibodies that specifically inhibit mitochondrial creatine kinase (MtCK) activity have been developed. In this study, we measured the serum MtCK activity in HIV-1-infected individuals (n = 100) by employing a novel method using these antibodies. The mean serum MtCK activity in 44 patients treated with highly active antiretroviral therapy (HAART) including tenofovir disoproxil fumarate (TDF) was 16.0 IU/L. The MtCK activity was significantly higher in patients receiving TDF than in those receiving HAART without TDF (3.4 IU/L) or in naïve patients (6.9 IU/L) (Tukey-Kramer test, p < 0.0001 and p = 0.0029, respectively). The serum MtCK activity reached a plateau at 1 month after the initiation of TDF administration and decreased upon discontinuation. It showed no significant correlation with the trough plasma TDF concentration, serum creatinine level, or red blood cell count. The activity was elevated in 75% of the patients receiving TDF, and this elevation was specific to TDF; it was not observed with other anti-HIV drugs. In addition, our report emphasizes the careful interpretation of creatine kinase-MB (CK-MB) test results in patients receiving TDF because MtCK in serum could cause false-positive results on a conventional CK-MB test, which does not include MtCK-specific inhibitory antibodies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Anti-HIV Agents |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Organophosphonates |2 NLM | |
| 650 | 7 | |a Tenofovir |2 NLM | |
| 650 | 7 | |a 99YXE507IL |2 NLM | |
| 650 | 7 | |a Creatine Kinase, Mitochondrial Form |2 NLM | |
| 650 | 7 | |a EC 2.7.3.2 |2 NLM | |
| 650 | 7 | |a Adenine |2 NLM | |
| 650 | 7 | |a JAC85A2161 |2 NLM | |
| 700 | 1 | |a Yoshino, Munehiro |e verfasserin |4 aut | |
| 700 | 1 | |a Yagura, Hiroki |e verfasserin |4 aut | |
| 700 | 1 | |a Hirota, Kazuyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Yonemoto, Hitoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Bando, Hiroki |e verfasserin |4 aut | |
| 700 | 1 | |a Yajima, Keishiro |e verfasserin |4 aut | |
| 700 | 1 | |a Koizumi, Yusuke |e verfasserin |4 aut | |
| 700 | 1 | |a Otera, Hiroshi |e verfasserin |4 aut | |
| 700 | 1 | |a Tominari, Shinjiro |e verfasserin |4 aut | |
| 700 | 1 | |a Nishida, Yasuharu |e verfasserin |4 aut | |
| 700 | 1 | |a Kuwahara, Takeshi |e verfasserin |4 aut | |
| 700 | 1 | |a Uehira, Tomoko |e verfasserin |4 aut | |
| 700 | 1 | |a Shirasaka, Takuma |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy |d 1996 |g 18(2012), 5 vom: 21. Okt., Seite 675-82 |w (DE-627)NLM095488073 |x 1437-7780 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2012 |g number:5 |g day:21 |g month:10 |g pages:675-82 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10156-012-0393-8 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2012 |e 5 |b 21 |c 10 |h 675-82 | ||